Blog
RSS FeedPosted by Michael Wonder on 10 Jun 2021
Yuhan's Leclaza to be cheaper than AstraZeneca's Tagrisso
10 June 2021 - The price of Yuhan's third generation epidermal growth factor receptor tyrosine kinase inhibitor for treating patients ...
Posted by Michael Wonder on 27 May 2021
'Anticancer drug should extend life for 22 months to get insurance benefits'
27 May 2021 - A research team at National Cancer Center has found that the public believes that for an ...
Posted by Michael Wonder on 27 May 2021
7 out of 10 Koreans want cheaper drug with same ingredient
27 May 2021 - Seven out of 10 Koreans want to lower the drug cost by choosing a cheaper generic ...
Posted by Michael Wonder on 24 May 2021
Why is Tagrisso not reimbursable as first-line treatment in Korea?
24 May 2021 - Osimertinib (Tagrisso) has transformed the treatment paradigm for epidermal growth factor receptor mutation positive non-small cell ...
Posted by Michael Wonder on 19 May 2021
‘Use effective drugs in early multiple myeloma to prevent relapse’
19 May 2021 - Multiple myeloma patients suffer frequent recurrences, and treatment response rates and response durations plummet along with ...
Posted by Michael Wonder on 14 May 2021
‘More reimbursement needed for hepatocellular carcinoma’
14 May 2021 - “Unlike other cancers, hepatocellular carcinoma is mostly diagnosed non-invasively. But this has not been reflected in ...
Posted by Michael Wonder on 13 May 2021
Eisai Korea to stop supply of blood cancer drug Symbenda this year
13 May 2021 - Symbenda (bendamustine), a treatment for blood cancer, is expected to become unavailable in Korea within this ...
Posted by Michael Wonder on 05 May 2021
Gilead readies to sell anticancer drug Trodelvy in Korea
4 May 2021 - Gilead’s antibody-drug conjugate Trodelvy (sacituzumab govitecan) has won the Ministry of Food and Drug Safety’s designation ...
Posted by Michael Wonder on 15 Apr 2021
Drug pricing policy in South Korea revised to ‘tiered pricing system’
14 April 2021 - The government announced a plan to restructure the generic drug pricing system with the main goal ...
Posted by Michael Wonder on 14 Apr 2021
Petition filed for better access to haemophilia A drug
14 April 2021 - Parents of paediatric patients with haemophilia A are demanding the regulator to change the criteria for ...
Posted by Michael Wonder on 07 Apr 2021
Janssen's prostate cancer drug gets reimbursement for mHSPC
6 April 2021 - Janssen said Tuesday that the government began providing health insurance benefits for its prostate cancer therapy ...
Posted by Michael Wonder on 17 Mar 2021
Zytiga to get insurance benefit for primary therapy in metastatic hormone-sensitive prostate cancer
17 March 2021 - Janssen Korea’s prostate cancer drug Zytiga (ingredient: abiraterone acetate) will get expanded insurance benefits for the ...
Posted by Michael Wonder on 07 Mar 2021
Primary dyslipidaemia drug Praluent gets insurance benefit
5 March 2021 - Sanofi-Aventis Korea’s primary dyslipidaemia treatment Praluent (alirocumab) has won health insurance benefits, the government said. ...
Posted by Michael Wonder on 24 Feb 2021
Takeda’s drug for acute hereditary angioedema seizure to get larger benefits
24 February 2021 - Takeda Pharmaceutical Korea said that the Ministry of Health and Welfare would grant expanded reimbursement for ...
Posted by Michael Wonder on 24 Feb 2021
Anti-cancer drugs Ninlaro, Lutathera to get insurance benefits from March
24 February 2021 - Takeda’s multiple myeloma treatment Ninlaro (ixazomib) and Novartis’ neuroendocrine tumour drug Lutathera (lutetium oxodotreotide) will get ...